Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Shattuck Labs, Inc. (STTK : NSDQ)

• Company Description    Shattuck Labs Inc. is a clinical-stage biotechnology company. It engages in development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of cancer and autoimmune disease. The company's wholly owned program includes SL-172154. It operates principally in Durham, North Carolina and Austin, Texas. Shattuck Labs Inc. is based in Austin, United States. Number of Employees: 40

• Price / Volume Information    Yesterday's Closing Price: $5.49 Daily Weekly Monthly 20 Day Moving Average: 1,384,827 shares Shares Outstanding: 100.36 (millions) Market Capitalization: $550.99 (millions) Beta: 1.09 52 Week High: $8.33 52 Week Low: $1.72 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -13.00% -12.08% 12 Week -23.64% -25.51% Year To Date 50.41% 37.05%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 500 W. 5TH STREET SUITE 1200 - AUSTIN,TX 78701 USA ph: 512-900-4690 fax: - investorrelations@shattucklabs.com http://www.shattucklabs.com

• General Corporate Information    Officers Taylor Schreiber - Chief Executive Officer and Director George Golumbeski - Chairman Andrew R. Neill - Chief Financial Officer Helen M. Boudreau - Director Neil Gibson - Director Peer Information Shattuck Labs, Inc. (CORR.) Shattuck Labs, Inc. (RSPI) Shattuck Labs, Inc. (CGXP) Shattuck Labs, Inc. (BGEN) Shattuck Labs, Inc. (GTBP) Shattuck Labs, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 82024L103 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/05/26 Share - Related Items Shares Outstanding: 100.36 Most Recent Split Date: (:1) Beta: 1.09 Market Capitalization: $550.99 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.11 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.45 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/05/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.62 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 50.00% vs. Previous Quarter: 7.69% Sales Growth vs. Year Ago Period: -66.63% vs. Previous Quarter: -% ROE 09/30/26 - - 06/30/26 - -43.57 03/31/26 - -60.73 ROA 09/30/26 - - 06/30/26 - -40.90 03/31/26 - -55.75 Current Ratio 09/30/26 - - 06/30/26 - 27.59 03/31/26 - 22.07 Quick Ratio 09/30/26 - - 06/30/26 - 27.59 03/31/26 - 22.06 Operating Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Net Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Pre-Tax Margin 09/30/26 - - 06/30/26 - -5,256.80 03/31/26 - -4,987.40 Book Value 09/30/26 - - 06/30/26 - 2.10 03/31/26 - 1.27 Inventory Turnover 09/30/26 - - 06/30/26 - - 03/31/26 - - Debt-to-Equity 09/30/26 - - 06/30/26 - 0.00 03/31/26 - 0.00 Debt-to-Capital 09/30/26 - - 06/30/26 - 0.00 03/31/26 - 0.00

Powered by Zacks Investment Research ©